Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: Role of brain-derived neurotrophic factor

Neuroscience

Volumn 223, Issue , 2012, Pages 219-224

  Liu, C Y ^a   Jiang, X X ^a   Zhu, Y H ^a   Wei, D N ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Antidepressant; BDNF; FST; LH; mGluR; MPEP

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; METABOTROPIC RECEPTOR ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DOWN REGULATION; DRUG DOSE COMPARISON; ESCAPE BEHAVIOR; FORCED SWIMMING TEST; IMMOBILIZATION; LEARNED HELPLESSNESS; LOCOMOTION; MALE; NEUROBIOLOGY; NONHUMAN; OLFACTORY BULBECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ESCAPE REACTION; HELPLESSNESS, LEARNED; IMMOBILITY RESPONSE, TONIC; MALE; MOTOR ACTIVITY; OLFACTORY BULB; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SWIMMING;

EID: 84865832806     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.08.010     Document Type: Article

References (30)

1. Attucci S., Carla V., Mannaioni G., Moroni F. Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br J Pharmacol 2001, 132:799-806.
2. Awad H., Hubert G.W., Smith Y., Levey A.I., Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 2000, 20:7871-7879.
3. Belozertseva I.V., Kos T., Popik P., Danysz W., Bespalov A.Y. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007, 17:172-179.
4. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
5. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004, 5:11-25.
6. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
7. Greene J., Banasr M., Lee B., Warner-Schmidt J., Duman R.S. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009, 34:2459-2468.
8. Hajszan T., Dow A., Warner-Schmidt J.L., Szigeti-Buck K., Sallam N.L., Parducz A., Leranth C., Duman R.S. Remodeling of hippocampal spine synapses in the rat learned helplessness model of depression. Biol Psychiatry 2009, 65:392-400.
9. Heidbreder C.A., Bianchi M., Lacroix L.P., Faedo S., Perdona E., Remelli R., Cavanni P., Crespi F. Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse 2003, 50:269-276.
10. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
11. Legutko B., Szewczyk B., Pomierny-Chamiolo L., Nowak G., Pilc A. Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacol Rep 2006, 58:427-430.
12. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
13. Li X., Need A.B., Baez M., Witkin J.M. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006, 319:254-259.
14. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15:525-539.
15. Manji H.K., Zarate C.A. Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics. Mol Psychiatry 2002, 7(Suppl. 1):S1-S7.
16. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33:2080-2092.
17. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
18. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat Neurosci 2010, 13:1161-1169.
19. Pilc A., Chaki S., Nowak G., Witkin J.M. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2008, 75:997-1006.
20. Pilc A., Klodzinska A., Branski P., Nowak G., Palucha A., Szewczyk B., Tatarczynska E., Chojnacka-Wojcik E., Wieronska J.M. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 2002, 43:181-187.
21. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
22. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
23. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007, 18:391-418.
24. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001, 132:1423-1430.
25. Thomas L.S., Jane D.E., Gasparini F., Croucher M.J. Glutamate release inhibiting properties of the novel mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology 2001, 41:523-527.
26. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
27. Wieronska J.M., Szewczyk B., Branski P., Palucha A., Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 2002, 23:213-216.
28. Witkin J.M., Marek G.J., Johnson B.G., Schoepp D.D. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 2007, 6:87-100.
29. Zarate C.A., Quiroz J., Payne J., Manji H.K. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002, 36:35-83.
30. Zhao X., Sun L., Jia H., Meng Q., Wu S., Li N., He S. Isolation rearing induces social and emotional function abnormalities and alters glutamate and neurodevelopment-related gene expression in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1173-1177.